PT  - JOURNAL ARTICLE
AU  - Kazuya Masuda
AU  - Hitoshi Shigeoka
TI  - Education and Later-life Mortality: Evidence from a School Reform in Japan
AID  - 10.1101/2023.07.10.23292439
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.07.10.23292439
4099  - http://medrxiv.org/content/early/2023/07/12/2023.07.10.23292439.short
4100  - http://medrxiv.org/content/early/2023/07/12/2023.07.10.23292439.full
AB  - We examine the mortality effects of a 1947 school reform in Japan, which extended compulsory schooling from primary to secondary school by as much as 3 years. The abolition of secondary school fees also indicates that those affected by the reform likely came from disadvantaged families who could have benefited the most from schooling. Even in this relatively favorable setting, we fail to find that the reform improved later-life mortality up to the age of 87 years, although it significantly increased years of schooling. This finding suggests limited health returns to schooling at the lower level of educational attainment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMasuda acknowledges financial support from JSPS KAKENHI (22H00847, 19K13677). Shigeoka acknowledges financial support from JSPS KAKENHI (23H00828, 22H00057, 22H00847, 22H05009).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Mortality, outpatient and inpatient data can be accessed through the Ministry of Health, Labour and Welfare in Japan.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesMortality, outpatient and inpatient data can be accessed through the Ministry of Health, Labour and Welfare in Japan.